Blackstone Inc.
BX
$106.61
-2.37%
Blackstone Inc. is the world's largest alternative asset manager, operating private equity, real estate/real assets, credit and insurance, and multi-asset investing businesses across institutional and high-net-worth channels, with $1.346 trillion in total assets under management ($961.6 billion fee-earning) as of June 2026. Its scale, brand, and perpetual-capital vehicles (BREIT, BCRED, BXPE) make it the platform incumbent of private markets rather than a niche specialist, with credit and insurance now the largest fee-earning AUM block at 33% and real assets at 29%. The current investor debate centers on whether Blackstone can convert record dry powder and a recovering realization environment into accelerating fee-related earnings and carried interest, against a backdrop of elevated rates, soft real estate marks, and a stock that has de-rated sharply over the past year. Recent quarterly results showed revenue growth reaccelerating to roughly 28% year over year with net income of $1.23 billion, yet the shares have lagged the market dramatically, reflecting investor skepticism about deployment pace, fundraising momentum, and the durability of performance fees in a slower exit market.…
BX
Blackstone Inc.
$106.61
Related headlines
BX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Blackstone Inc.'s 12-month outlook, with a consensus price target around $139.91 and implied upside of +31.2% versus the current price.
Average Target
$139.91
0 analysts
Implied Upside
+31.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$116 - $171
Analyst target range
Coverage is broad, with 22 analysts and a consensus recommendation of "buy" (mean rating 2.08 on a scale where lower is more bullish). The average target price is $140.77, implying +32.0% upside from the current $106.61, and consensus forward EPS of $9.13 and revenue of $16.29 billion (range $15.25-$17.41 billion) underpin that optimism. Sentiment therefore leans clearly bullish on fundamentals even as the tape is deeply bearish — a classic divergence that often precedes either a violent re-rating or a wave of estimate cuts.
The target range is wide, from a low of $116.00 (+8.8%) to a high of $184.00 (+72.6%), signaling meaningful disagreement about the pace of realizations and fundraising. The high target likely assumes a normalization of carried interest, continued AUM growth toward and beyond $1.35 trillion, and multiple re-expansion toward historical norms; the low target implies only modest recovery and continued margin pressure from a slow exit environment. Institutional ratings show a stable-to-cautiously-constructive pattern — Oppenheimer reiterated Outperform on August 27, Argus reiterated Buy on July 30, and RBC and TD Cowen maintained Outperform/Buy in late July, while Goldman Sachs and JP Morgan stayed Neutral and Barclays Equal Weight — indicating the bulls are not being upgraded aggressively and the neutral camp remains anchored, consistent with a stock that must prove its earnings recovery before the consensus target gap closes.
Bulls vs Bears: BX Investment Factors
The bear case currently has stronger near-term evidence: price action is a confirmed downtrend with -32.5% one-year returns, relative strength of -48.0 versus SPY, and a stock sitting 3.0% off its 52-week low with accelerating one-month weakness. The bull case rests on valuation and fundamentals — 14.4x forward earnings, 28.5% revenue growth, 62% EBITDA margins, and a $140.77 average target implying 32% upside — but those have been true for months while the stock kept falling. The single most important tension is whether the $9.13 forward EPS estimate is achievable: it requires earnings to roughly triple from GAAP trailing levels, and if realizations and carried interest normalize, the 14.4x multiple is deeply undervalued; if the exit environment stays frozen and estimates get cut, there is little cushion at 13.9x book. Until price reclaims the $120s or a quarter confirms the earnings recovery, the tape and the fundamentals are telling opposite stories, and the market is voting with the tape.
Bullish
- Forward PE near multi-year lows: At $106.61, BX trades at 14.40x consensus forward EPS of $9.13, versus a trailing PE of 39.73x and a historical PE band of roughly 15x (Q3 2021) to over 50x (Q3 2025). Against alternative managers typically trading in the high-teens to low-20s forward, this implies a 25-35% discount on the most economically meaningful metric.
- Revenue reaccelerating at 28.5% YoY: Q2 2026 revenue of $4.769 billion grew 28.49% from $3.712 billion a year earlier and rose sequentially from $4.102 billion in Q1 2026, which itself grew 39.3% YoY. The acceleration is broad-based, with management and advisory fees of $2.266 billion plus investment income of $2.473 billion.
- Analyst consensus implies 32% upside: 22 analysts carry a 'buy' consensus (mean rating 2.08) with an average target of $140.77, +32.0% from $106.61, and a range of $116.00 to $184.00. Oppenheimer reiterated Outperform on August 27 and Argus reiterated Buy on July 30, indicating fundamental conviction has not broken even as the tape has.
- Elite profitability and ROE: Q2 2026 operating margin was 61.9%, EBITDA margin 62.5%, and gross margin 98.8%, with ROE of 34.8% and ROA of 14.3%. TTM free cash flow of $4.415 billion and operating cash of $1.941 billion in Q2 show the franchise still converts earnings into cash.
Bearish
- Falling knife: -32.5% in one year: BX is down 32.51% over 12 months and 32.87% YTD versus SPY's +15.53% and +11.93%, a relative strength gap of -48.04 over one year. At $106.61 the stock sits just 3.0% above its 52-week low and 35.4% below its high, with a max drawdown of -45.88%.
- Momentum deteriorating, not stabilizing: The one-month decline of -13.64% is steeper than the three-month (-15.99%) and six-month (-17.41%) figures, and the latest session fell -2.37% to $106.61 on 7.1 million shares. Relative strength of -14.86 over one month versus SPY shows the selloff is intensifying with no base forming.
- Earnings quality is volatile and lumpy: Q2 2026 net margin of 25.8% compares with 15.8% in Q1 2026 and 23.3% in Q4 2025, and operating margin swung from 38.8% to 61.9% in a single quarter. Performance-linked and investment income of $2.473 billion plus $159 million of incentive fees drive results, a mix far more cyclical than recurring management fees.
- Payout exceeds earnings: The payout ratio of 1.99 against a 5.0% dividend yield means distributions are roughly double earnings, funded partly by balance-sheet capacity. With debt-to-equity at 1.536x and a current ratio of 0.914, the company relies on short-term funding and external capital markets.
BX Technical Analysis
Blackstone is in a sustained downtrend, with the stock down 32.51% over the past year and 32.87% year to date, a stark contrast to the S&P 500's +15.53% one-year and +11.93% YTD returns. At $106.61, the shares sit just 3.0% above the 52-week low of $101.73 and roughly 35.4% below the 52-week high of $165.14, placing the stock at approximately 8.4% of its 52-week range — deep in the bottom decile. That positioning signals persistent distribution and a falling-knife profile rather than a value opportunity, with the max drawdown of -45.88% underscoring how severe the de-rating has been.
Short-term momentum is decisively negative and accelerating to the downside: the stock is down 13.64% over the past month and 15.99% over three months, versus a +1.22% one-month and +2.69% three-month gain for SPY, producing relative strength of -14.86 and -18.69 respectively. The one-month decline is steeper than the three-month and six-month (-17.41%) figures, indicating the selloff is intensifying rather than stabilizing, and the most recent session saw a -2.37% drop to $106.61 on volume of 7.1 million shares. With the 1-month trend confirming rather than diverging from the 1-year downtrend, there is no technical evidence of mean reversion or a base forming; RSI is not provided but the price action is consistent with oversold-to-weakening conditions.
Key support sits at the 52-week low of $101.73, only 4.6% below the current price; a decisive break there would likely trigger momentum-driven selling and open a new leg lower, while resistance is anchored at the $165.14 52-week high, with intermediate supply likely near the $130-$145 zone where the stock repeatedly failed in July and August. The beta of 1.587 means Blackstone is roughly 59% more volatile than the market, so a 10% SPY drawdown could translate into a mid-teens decline for BX — position sizing and stop discipline are critical. The short ratio of 5.39 days-to-cover indicates meaningful bearish positioning that could fuel sharp squeezes on any positive catalyst, but until price reclaims at least the $120s, the path of least resistance remains lower.
Beta
1.59
1.59x market volatility
Max Drawdown
-45.9%
Largest decline past year
52-Week Range
$102-$165
Price range past year
Annual Return
-32.5%
Cumulative gain past year
| Period | BX Return | S&P 500 |
|---|---|---|
| 1m | -13.6% | +0.2% |
| 3m | -16.0% | +2.9% |
| 6m | -17.4% | +8.4% |
| 1y | -32.5% | +14.9% |
| ytd | -32.9% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BX Fundamental Analysis
Revenue is reaccelerating strongly: Q2 2026 revenue reached $4.769 billion, up 28.49% year over year from $3.712 billion in Q2 2025, and up sequentially from $4.102 billion in Q1 2026. The multi-quarter trajectory shows clear acceleration — Q1 2026 revenue of $4.102 billion versus Q1 2025's $2.945 billion (+39.3%), Q4 2025's $4.360 billion versus $2.818 billion a year earlier, and Q3 2025's $2.812 billion versus $2.998 billion — with the Q2 2026 print the strongest of the cycle. Segment detail shows management and advisory fees of $2.266 billion plus total investment income of $2.473 billion and incentive fees of $159 million, meaning performance-linked and investment income are doing the heavy lifting; that mix is inherently more volatile than recurring management fees and explains why the market discounts the growth.
Profitability is robust at the operating line: Q2 2026 net income was $1.229 billion (25.8% net margin), operating income $2.953 billion (61.9% operating margin), and EBITDA $2.979 billion (62.5% EBITDA margin), with gross margin of 98.8%. Margins have been volatile quarter to quarter — Q1 2026 net margin was 15.8% and operating margin 38.8%, versus Q4 2025's 23.3% and 54.2% — reflecting the lumpy nature of realizations and mark-to-market gains rather than a structural deterioration. The TTM net margin of 21.8% and operating margin of 51.9% remain healthy for an asset manager, though the trailing EPS of $0.025 is distorted by GAAP accounting for consolidated funds and is not representative of distributable earnings power.
Balance sheet and cash flow are adequate but leverage is meaningful: debt-to-equity stands at 1.536x, the current ratio is 0.914 (below 1.0, indicating reliance on short-term funding), and ROE is a strong 34.8% with ROA of 14.3%. TTM free cash flow is $4.415 billion, but quarterly FCF is highly uneven — $1.909 billion in Q2 2026, $958 million in Q1 2026, -$25 million in Q4 2025, and $1.574 billion in Q3 2025 — and the payout ratio of 1.99 (dividend yield 5.0%) means distributions currently exceed earnings, funded partly by balance-sheet capacity. The company generates enough operating cash ($1.941 billion in Q2 2026) to fund operations, but its growth engine depends on raising and deploying third-party capital, so external financing conditions remain a key risk.
Quarterly Revenue
$4.8B
2026-06
Revenue YoY Growth
+28.5%
YoY Comparison
Gross Margin
98.8%
Latest Quarter
Free Cash Flow
$4.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BX Overvalued?
Because trailing net income is positive, the PE ratio is the primary metric: BX trades at 39.73x trailing earnings versus a forward PE of 14.40x, an extraordinary 64% compression that implies the market expects earnings to roughly triple. That gap is largely an artifact of GAAP accounting — the $0.025 trailing EPS versus a consensus forward EPS of $9.13 reflects consolidated-fund accounting distortions — so the forward multiple is the more economically meaningful anchor, and at 14.4x forward earnings the stock screens cheap relative to its own history and to the quality of its franchise.
On other multiples the picture is mixed: price-to-book is 13.89x, price-to-sales 8.70x, EV/sales 7.33x, and EV/EBITDA 27.06x, with a PEG of 5.53 and price-to-cash-flow of 64.70x. Against a sector where alternative managers typically trade in the high-teens to low-20s on forward earnings, the 14.4x forward PE represents a discount of roughly 25-35%, while the 13.9x book multiple is a premium reflecting Blackstone's asset-light, fee-based model and 34.8% ROE. The discount on earnings is arguably unjustified given 28.5% revenue growth and 62% EBITDA margins, but the premium on book and sales suggests the market is not uniformly bearish — it is specifically skeptical of near-term earnings realization.
Historically, BX's PE has ranged from roughly 15x (Q3 2021) to over 50x (Q3 2025), with the Q2 2026 reading of 18.7x near the low end of that band, and its price-to-book of 13.89x compares with a historical range of roughly 7.2x (Q4 2022) to 16.8x (Q3 2024), placing it in the middle-to-upper portion. The forward PE of 14.4x is near multi-year lows, suggesting the market is pricing in pessimistic realization and fundraising assumptions; if those normalize, multiple expansion alone could drive substantial upside, but if the earnings recovery embedded in the forward estimate disappoints, the stock has little valuation cushion at 13.9x book.
PE
39.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~53x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and leverage. Q2 2026 net income of $1.229 billion was flattered by $2.473 billion of investment income and $159 million of incentive fees, both mark-to-market and realization dependent, which is why net margin swung from 15.8% in Q1 2026 to 25.8% in Q2. The payout ratio of 1.99 against a 5.0% yield means distributions exceed earnings, and with debt-to-equity at 1.536x and a current ratio of 0.914, the firm depends on short-term funding and continued capital raising. Quarterly free cash flow is highly uneven — $1.909 billion in Q2 2026 versus -$25 million in Q4 2025 — so a slow exit quarter can quickly strain distribution coverage.
Market and competitive risks are dominated by valuation compression and rate sensitivity. Beta of 1.587 means a 10% SPY drawdown could translate into a mid-teens decline for BX, and the stock has already delivered -48.0 relative strength versus the S&P over one year. At 13.89x book and 8.70x sales, the premium to the sector leaves room for further de-rating if realizations disappoint, and the 27.06x EV/EBITDA is not cheap in absolute terms. Competitive pressure from other mega-alternatives managers chasing the same institutional allocations, plus a high-rate environment that raises the cost of leverage in portfolio companies and slows exit activity, directly threatens the carried-interest engine.
Worst case: a prolonged freeze in exits combines with fundraising deceleration and soft real estate marks, forcing consensus forward EPS of $9.13 to be cut materially and the multiple to stay compressed. A break below the 52-week low of $101.73 — only 4.6% below the current $106.61 — would likely trigger momentum selling toward the analyst low target of $116.00 being breached on the downside, with the -45.88% max drawdown as a guide to how far a full de-rating can run. From $106.61, a retest of the 52-week low implies roughly -4.6%, while a repeat of the historical max drawdown from the 52-week high of $165.14 implies a downside scenario in the $89-$95 range, or roughly -11% to -16% from here.

